Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Ross John Porter, Caroline Andrews, Daniel Paul Brice, Scott Kenneth Durum, Mairi Hall McLean (Corresponding Author)

Research output: Contribution to journalReview article

Abstract

Inflammatory bowel disease (IBD) describes chronic relapsing remitting inflammation of the gastrointestinal tract including ulcerative colitis and Crohn’s disease. The prevalence of IBD is rising across the globe. Despite a growing therapeutic arsenal, current medical treatments are not universally effective, do not induce lasting remission in all, or are accompanied by short and long-term adverse effects. Therefore, there is a clinical need for novel therapeutic strategies for IBD. Current treatments for IBD mainly manipulate the immune system for therapeutic gain by inhibiting pro-inflammatory activity. There is a robust endogenous immunoregulatory capacity within the repertoire of both innate and adaptive immune responses. An alternative treatment strategy for IBD is to hijack and bolster this endogenous capability for therapeutic gain. This review explores this hypothesis and presents current evidence for this therapeutic direction in immune cell function, cytokine biology, and alternative mechanisms of immunoregulation such as microRNA, oligonucleotides and the endocannabinoid system.
Original languageEnglish
Pages (from-to)2123-2134
Number of pages12
JournalInflammatory Bowel Diseases
Volume24
Issue number10
Early online date18 Jul 2018
DOIs
Publication statusPublished - 15 Sep 2018

Fingerprint

Inflammatory Bowel Diseases
Anti-Inflammatory Agents
Therapeutics
Endocannabinoids
Adaptive Immunity
MicroRNAs
Ulcerative Colitis
Innate Immunity
Oligonucleotides
Crohn Disease
Gastrointestinal Tract
Immune System
Cytokines
Inflammation

Keywords

  • Inflammatory Bowel Disease
  • immunoregulation
  • cytokine
  • ulcerative colitis
  • Crohn's disease
  • treatment

Cite this

Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease? / Porter, Ross John; Andrews, Caroline; Brice, Daniel Paul; Durum, Scott Kenneth; McLean, Mairi Hall (Corresponding Author).

In: Inflammatory Bowel Diseases, Vol. 24, No. 10, 15.09.2018, p. 2123-2134.

Research output: Contribution to journalReview article

Porter, Ross John ; Andrews, Caroline ; Brice, Daniel Paul ; Durum, Scott Kenneth ; McLean, Mairi Hall. / Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?. In: Inflammatory Bowel Diseases. 2018 ; Vol. 24, No. 10. pp. 2123-2134.
@article{75128111a52040eabc65906f8cfab7ad,
title = "Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?",
abstract = "Inflammatory bowel disease (IBD) describes chronic relapsing remitting inflammation of the gastrointestinal tract including ulcerative colitis and Crohn’s disease. The prevalence of IBD is rising across the globe. Despite a growing therapeutic arsenal, current medical treatments are not universally effective, do not induce lasting remission in all, or are accompanied by short and long-term adverse effects. Therefore, there is a clinical need for novel therapeutic strategies for IBD. Current treatments for IBD mainly manipulate the immune system for therapeutic gain by inhibiting pro-inflammatory activity. There is a robust endogenous immunoregulatory capacity within the repertoire of both innate and adaptive immune responses. An alternative treatment strategy for IBD is to hijack and bolster this endogenous capability for therapeutic gain. This review explores this hypothesis and presents current evidence for this therapeutic direction in immune cell function, cytokine biology, and alternative mechanisms of immunoregulation such as microRNA, oligonucleotides and the endocannabinoid system.",
keywords = "Inflammatory Bowel Disease, immunoregulation, cytokine, ulcerative colitis, Crohn's disease, treatment",
author = "Porter, {Ross John} and Caroline Andrews and Brice, {Daniel Paul} and Durum, {Scott Kenneth} and McLean, {Mairi Hall}",
note = "Drs. Andrews and Durum are supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, National Institutes of Health, USA.",
year = "2018",
month = "9",
day = "15",
doi = "10.1093/ibd/izy230",
language = "English",
volume = "24",
pages = "2123--2134",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

AU - Porter, Ross John

AU - Andrews, Caroline

AU - Brice, Daniel Paul

AU - Durum, Scott Kenneth

AU - McLean, Mairi Hall

N1 - Drs. Andrews and Durum are supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, National Institutes of Health, USA.

PY - 2018/9/15

Y1 - 2018/9/15

N2 - Inflammatory bowel disease (IBD) describes chronic relapsing remitting inflammation of the gastrointestinal tract including ulcerative colitis and Crohn’s disease. The prevalence of IBD is rising across the globe. Despite a growing therapeutic arsenal, current medical treatments are not universally effective, do not induce lasting remission in all, or are accompanied by short and long-term adverse effects. Therefore, there is a clinical need for novel therapeutic strategies for IBD. Current treatments for IBD mainly manipulate the immune system for therapeutic gain by inhibiting pro-inflammatory activity. There is a robust endogenous immunoregulatory capacity within the repertoire of both innate and adaptive immune responses. An alternative treatment strategy for IBD is to hijack and bolster this endogenous capability for therapeutic gain. This review explores this hypothesis and presents current evidence for this therapeutic direction in immune cell function, cytokine biology, and alternative mechanisms of immunoregulation such as microRNA, oligonucleotides and the endocannabinoid system.

AB - Inflammatory bowel disease (IBD) describes chronic relapsing remitting inflammation of the gastrointestinal tract including ulcerative colitis and Crohn’s disease. The prevalence of IBD is rising across the globe. Despite a growing therapeutic arsenal, current medical treatments are not universally effective, do not induce lasting remission in all, or are accompanied by short and long-term adverse effects. Therefore, there is a clinical need for novel therapeutic strategies for IBD. Current treatments for IBD mainly manipulate the immune system for therapeutic gain by inhibiting pro-inflammatory activity. There is a robust endogenous immunoregulatory capacity within the repertoire of both innate and adaptive immune responses. An alternative treatment strategy for IBD is to hijack and bolster this endogenous capability for therapeutic gain. This review explores this hypothesis and presents current evidence for this therapeutic direction in immune cell function, cytokine biology, and alternative mechanisms of immunoregulation such as microRNA, oligonucleotides and the endocannabinoid system.

KW - Inflammatory Bowel Disease

KW - immunoregulation

KW - cytokine

KW - ulcerative colitis

KW - Crohn's disease

KW - treatment

U2 - 10.1093/ibd/izy230

DO - 10.1093/ibd/izy230

M3 - Review article

VL - 24

SP - 2123

EP - 2134

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -